Michalina Jezierska

Mrs. Michalina Jezierska

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
MJMichalina Jezierska
Michalina Jezierska
AGAda Gawrychowska
Ada Gawrychowska
JSJoanna Stefanowicz
Joanna Stefanowicz
Germ cell tumors (GCTs) are a heterogenous group of neoplasms in children and young adults, in which serum tumor markers have been demonstrated to be highly sensitive diagnostic and monitoring tools. The known "old" serum biomarkers, alpha-fetoprotein (AFP), human choriogonadotropin (β-hCG) and lactate dehydrogenase (LDH), have some limitations in sensitivity and specificity. MIRNAs from the miR-371~373 (chromosomal locus 19q13.41) and miR-302/367 (4q25) clusters are universally over-expressed in malignant GCT tissue samples. The levels of miRNAs from these clusters are elevated in the serum. They seem to be highly sensitive and specific in malignant GCTs diagnosis and disease assessment during treatment and follow-up. The aim of our review was to present the role of serum tumor markers in the clinical staging, treatment monitoring and follow-up of pediatric patients with GCTs and show new possibilities. The serum levels of miRNAs seem to be a new, promising essential tool in the clinical management of GCTs.

31 October 2022 in Children
Verified
Journal Article
Open access
PDF file
MJMichalina Jezierska
Michalina Jezierska
JSJoanna Stefanowicz
Joanna Stefanowicz
Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), inhibitors of nitric oxide synthase, play important roles in many processes in the body. Most data in the literature concern their importance in adult chronic kidney disease (CKD). According to them, SDMA well reflects the glomerular filtration rate (GFR), and higher ADMA concentrations are associated with hypertension and higher mortality. In addition, both substances are recognised cardiovascular risk factors in CKD. The purpose of this review was to summarise the studies on dimethylarginines in renal diseases in children, about which we have much fewer data. The review focuses specifically on dimethylarginine’s relation to routinely used renal function parameters. Finally, we analysed 21 of the 55 articles published between 2003 and 2022 on dimethylarginines in kidney diseases in children (from birth to 18 years of age), obtained by searching PubMed/MEDLINE (search terms: “dimethylarginine” and “kidney”).

11 January 2022 in Medicina
Verified
Journal Article
Open access
PDF file
MJMichalina Jezierska
Michalina Jezierska
AOAnna Owczarzak
Anna Owczarzak
JSJoanna Stefanowicz
Joanna Stefanowicz
Background and Objectives: According to a recent Cochrane systematic review, renal impairment can develop in 0–84% of childhood cancer survivors in the future. The renal function impairment in this patient group can be related to nephrectomy, nephrotoxic agents therapy, abdominal radiotherapy, and combinations of these treatment methods. In this study, in a population of patients after anti-neoplastic therapy, with particular emphasis on patients after Wilms’ tumour treatment, we compared new substances which play role in the chronic kidney disease (CKD) pathogenesis (asymmetric dimethylarginine—ADMA, symmetric dimethylarginine—SDMA) with standard renal function markers (e.g., creatinine and cystatin C in serum, creatinine in urine, etc.) to assess the usefulness of the former. Materials and Methods: Eighty-four children, without CKD, bilateral kidney tumours, congenital kidney defects, or urinary tract infections, with a minimum time of 1 year after ending anti-neoplastic treatment, aged between 17 and 215 months, were divided into three groups: group 1—patients after nephroblastoma treatment (n = 21), group 2—after other solid tumours treatment (n = 44), and group 3—after lymphoproliferative neoplasms treatment (n = 19). The patients’ medical histories were taken and physical examinations were performed. Concentrations of blood urea nitrogen (BUN), creatinine, cystatin C, C-reactive protein (CRP), ADMA, and SDMA in blood and albumin in urine were measured, and a general urine analysis was performed. The SDMA/ADMA ratio, albumin–creatine ratio, and estimated glomerular filtration rate (eGFR) were calculated. eGFR was estimated by three equations recommended to the paediatric population by the KDIGO from 2012: the Schwartz equation (eGFR1), equation with creatinine and urea nitrogen (eGFR2), and equation with cystatin C (eGFR3). Results: Both the eGFR1 and eGFR2 values were significantly lower in group 1 than in group 3 (eGFR1: 93.3 (83.1–102.3) vs. 116.5 (96.8–126.9) mL/min/1.73 m2, p = 0.02; eGFR2: 82.7 (±14.4) vs. 94.4 (±11.9) mL/min/1.73 m2, p = 0.02). Additionally, there were weak positive correlations between SDMA and creatinine (p < 0.05, r = 0.24), and cystatin C (p < 0.05, r = 0.32) and weak negative correlations between SDMA and eGFR1 (p < 0.05, r = −0.25), eGFR2 (p < 0.05, r = −0.24), and eGFR3 (p < 0.05, r = −0.32). Conclusions: The usefulness of ADMA and SDMA in the diagnosis of renal functional impairment should be assessed in further studies. eGFR, calculated according to equations recommended for children, should be used in routine paediatric practice.

1 August 2023 in Acta Haematologica Polonica
Verified
Journal Article
Open access
PDF file
MJMichalina Jezierska
Michalina Jezierska
AOAnna Owczarzak
Anna Owczarzak
JSJoanna Stefanowicz
Joanna Stefanowicz
Introduction: Nephrotoxicity, as a side effect of antineoplastic treatment, can occur in childhood cancer survivors (CCSs). It worsens their quality of life especially if it leads to chronic kidney disease (CKD). Collagen turnover is known to be disturbed in CKD. Urinary type IV collagen (U-Col4) is recognized as an exponent of extracellular matrix synthesis and degradation in glomeruli and is thus involved in this turnover. The purpose of this study was to evaluate the usefulness of U-Col4 in assessing early renal impairment in CCSs. Material and methods: Seventy-eight CCSs, without CKD, bilateral kidney tumors, congenital kidney defects, urinary tract infections and diabetes, at least one year after ending antineoplastic treatment, and aged 1–18 years, were divided into three groups: 1) patients after nephroblastoma treatment (n = 18); 2) patients after other solid tumors treatment (n = 42); and 3) patients after anti-hamatopoietic and lymphatic system proliferative treatment (n = 18). Concentrations of creatinine and cystatin C in serum, and of albumin, creatinine, N-acetyl-β-D-glucosaminidase (NAG), and U-Col4 in urine, were measured, and a general urine analysis was performed. The albumin-creatinine ratio (ACR), the urine U-Col4/creatinine ratio, the urine NAG/creatinine ratio and the estimated glomerular filtration rate were calculated according to the Schwartz equation and the Filler equation. Results: We did not find any differences between the groups in the evaluated biochemical parameters. Weak negative correlations were found between U-Col4 and urine NAG/creatinine ratio (p = 0.02, R = –0.27) and ACR (p = 0.00, R = –0.39). Conclusions: Evaluation of the usefulness of U-Col4 in assessing early renal impairment in CCSs requires further study. CCSs should be monitored for potential complications of antineoplastic treatment, even many years after its completion. Introduction: Nephrotoxicity, as a side effect of antineoplastic treatment, can occur in childhood cancer survivors (CCSs). It worsens their quality of life especially if it leads to chronic kidney disease (CKD). Collagen turnover is known to be disturbed in CKD. Urinary type IV collagen (U-Col4) is recognized as an exponent of extracellular matrix synthesis and degradation in glomeruli and is thus involved in this turnover. The purpose of this study was to evaluate the usefulness of U-Col4 in assessing early renal impairment in CCSs. Material and methods: Seventy-eight CCSs, without CKD, bilateral kidney tumors, congenital kidney defects, urinary tract infections and diabetes, at least one year after ending antineoplastic treatment, and aged 1–18 years, were divided into three groups: 1) patients after nephroblastoma treatment (n = 18); 2) patients after other solid tumors treatment (n = 42); and 3) patients after anti-hamatopoietic and lymphatic system proliferative treatment (n = 18). Concentrations of creatinine and cystatin C in serum, and of albumin, creatinine, N-acetyl-β-D-glucosaminidase (NAG), and U-Col4 in urine, were measured, and a general urine analysis was performed. The albumin-creatinine ratio (ACR), the urine U-Col4/creatinine ratio, the urine NAG/creatinine ratio and the estimated glomerular filtration rate were calculated according to the Schwartz equation and the Filler equation. Results: We did not find any differences between the groups in the evaluated biochemical parameters. Weak negative correlations were found between U-Col4 and urine NAG/creatinine ratio (p = 0.02, R = –0.27) and ACR (p = 0.00, R = –0.39). Conclusions: Evaluation of the usefulness of U-Col4 in assessing early renal impairment in CCSs requires further study. CCSs should be monitored for potential complications of antineoplastic treatment, even many years after its completion.